With the Just Label It and Right2Know non-GMO campaigns building steam, GMO labeling still remains a topic of debate. Adam Eidinger, organic food activist and organizer of last year's Right2Know March, recounts his recent experience of speaking at Monsanto's shareholder meeting, and explains why GMO labeling may become a reality....
More
Most clinical research on an active ingredient is done under time constraint due to the high cost of clinical research. Thus, researchers often use high doses to achieve a measurable outcome. It is not necessarily advisable to consume long-term the dose used in a short-term clinical trial. A smaller dose may very well not only be advisable from an efficacy point of view, but also from a safety point of view. Olav E. Sandnes, President, Marine Ingredients
on Feb. 10, 2012